These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 21860040)

  • 1. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.
    Bechdolf A; Müller H; Stützer H; Wagner M; Maier W; Lautenschlager M; Heinz A; de Millas W; Janssen B; Gaebel W; Michel TM; Schneider F; Lambert M; Naber D; Brüne M; Krüger-Özgürdal S; Wobrock T; Riedel M; Klosterkötter J;
    Schizophr Bull; 2011 Sep; 37 Suppl 2(Suppl 2):S111-21. PubMed ID: 21860040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of First-Episode Psychosis in People at Clinical High Risk: A Randomized Controlled, Multicentre Trial Comparing Cognitive-Behavioral Therapy and Clinical Management Plus Low-Dose Aripiprazole or Placebo (PREVENT).
    Bechdolf A; Müller H; Hellmich M; de Millas W; Falkai P; Gaebel W; Gallinat J; Hasan A; Heinz A; Janssen B; Juckel G; Karow A; Krüger-Özgürdal S; Lambert M; Maier W; Meyer-Lindenberg A; Pützfeld V; Rausch F; Schneider F; Stützer H; Wobrock T; Wagner M; Zink M; Klosterkötter J
    Schizophr Bull; 2023 Jul; 49(4):1055-1066. PubMed ID: 37021666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal prevention of first psychotic episode through N-acetyl-l-cysteine and integrated preventive psychological intervention in individuals clinically at high risk for psychosis: Protocol of a randomized, placebo-controlled, parallel-group trial.
    Schmidt SJ; Hurlemann R; Schultz J; Wasserthal S; Kloss C; Maier W; Meyer-Lindenberg A; Hellmich M; Muthesius-Digón A; Pantel T; Wiesner PS; Klosterkötter J; Ruhrmann S;
    Early Interv Psychiatry; 2019 Dec; 13(6):1404-1415. PubMed ID: 30784233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
    Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
    J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.
    Streim JE; Porsteinsson AP; Breder CD; Swanink R; Marcus R; McQuade R; Carson WH
    Am J Geriatr Psychiatry; 2008 Jul; 16(7):537-50. PubMed ID: 18591574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
    Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MB; Bilenberg N; Stenstrøm AD; Pedersen J; Nyvang L; Madsen S; Lauritsen MB; Vernal DL; Thomsen PH; Paludan J; Werge TM; Winge K; Juul K; Gluud C; Skoog M; Wetterslev J; Jepsen JR; Correll CU; Fink-Jensen A; Fagerlund B
    BMC Psychiatry; 2014 Jul; 14():199. PubMed ID: 25015535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study.
    De Deyn P; Jeste DV; Swanink R; Kostic D; Breder C; Carson WH; Iwamoto T
    J Clin Psychopharmacol; 2005 Oct; 25(5):463-7. PubMed ID: 16160622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants.
    O'Donoghue B; Francey SM; Nelson B; Ratheesh A; Allott K; Graham J; Baldwin L; Alvarez-Jimenez M; Thompson A; Fornito A; Polari A; Berk M; Macneil C; Crisp K; Pantelis C; Yuen HP; Harrigan S; McGorry P
    Early Interv Psychiatry; 2019 Aug; 13(4):953-960. PubMed ID: 30024100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: Managing Adolescent first episode Psychosis: a feasibility study (MAPS).
    Pyle M; Broome MR; Joyce E; MacLennan G; Norrie J; Freeman D; Fowler D; Haddad PM; Shiers D; Hollis C; Smith J; Liew A; Byrne RE; French P; Peters S; Hudson J; Davies L; Emsley R; Yung A; Birchwood M; Longden E; Morrison AP
    Trials; 2019 Jul; 20(1):395. PubMed ID: 31272477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis.
    Farnia V; Shakeri J; Tatari F; Juibari TA; Yazdchi K; Bajoghli H; Brand S; Abdoli N; Aghaei A
    Am J Drug Alcohol Abuse; 2014 Jan; 40(1):10-5. PubMed ID: 24359506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.
    Keck PE; Calabrese JR; McQuade RD; Carson WH; Carlson BX; Rollin LM; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2006 Apr; 67(4):626-37. PubMed ID: 16669728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
    Glick ID; Mankoski R; Eudicone JM; Marcus RN; Tran QV; Assunção-Talbott S
    J Affect Disord; 2009 May; 115(1-2):18-26. PubMed ID: 19230981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.
    Rietdijk J; Dragt S; Klaassen R; Ising H; Nieman D; Wunderink L; Delespaul P; Cuijpers P; Linszen D; van der Gaag M
    Trials; 2010 Mar; 11():30. PubMed ID: 20307268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
    Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
    Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
    McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
    JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.